JPH09509578A - 組み込み可能な組み換えアデノウィルス、それらの製造及びそれらの治療的利用 - Google Patents
組み込み可能な組み換えアデノウィルス、それらの製造及びそれらの治療的利用Info
- Publication number
- JPH09509578A JPH09509578A JP7522730A JP52273095A JPH09509578A JP H09509578 A JPH09509578 A JP H09509578A JP 7522730 A JP7522730 A JP 7522730A JP 52273095 A JP52273095 A JP 52273095A JP H09509578 A JPH09509578 A JP H09509578A
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- gene
- itr
- cells
- adenovirus according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10361—Methods of inactivation or attenuation
- C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.感染細胞のゲノム中に組み込まれることができるカセットを含む欠失組み 換えアデノウィルス。 2.カセットが異種DNA配列及びゲノム中へのその組み込みを可能にする要 素を含むことを特徴とする請求の範囲第1項に記載のアデノウィルス。 3.カセットの組み込みを可能にする要素がウィルス起源のものであることを 特徴とする請求の範囲第2項に記載のアデノウィルス。 4.カセットが少なくとも1つのAAV逆方向末端反復塩基配列(ITR)及 び1つの異種DNA配列を含むことを特徴とする請求の範囲第3項に記載のアデ ノウィルス。 5.AAV ITRが異種DNA配列の下流又は上流に置かれることを特徴と する請求の範囲第4項に記載のアデノウィルス。 6.カセットがその端で2つのAAV ITRに接する少なくとも1つの異種 DNA配列を含むことを特徴とする請求の範囲第4項に記載のアデノウィルス。 7.ITRが絶対ITR又は、組み込み能力を抑制しない付加領域又は欠失を 有するITRであることを特徴とする請求の範囲第4〜6項の1つに記載のアデ ノウィルス。 8.ITRがAAV−2 ITRであることを特徴とする請求の範囲第3〜7 項の1つに記載のアデノウィルス。 9.異種DNA配列が治療的遺伝子を含むことを特徴とする請求の範囲第1〜 8項のいずれか1つに記載のアデノウィルス。 10.治療的遺伝子が治療的効果を有するタンパク質産物をコードす る遺伝子、1種又はそれ以上の抗原性ペプチドをコードする遺伝子、あるいはア ンチセンス遺伝子又は配列であることを特徴とする請求の範囲第11項に記載の アデノウィルス。 11.治療的遺伝子が酵素、血液誘導体、ホルモン、リンホカイン:インター ロイキン、インターフェロン、TNF、成長因子(エリスロポイエチン、G−C SF、M−CSF、GM−CSFなど)、神経伝達物質又はそれらの前駆体、あ るいは合成酵素、トロフィック因子:BDNF、CNTF、NGF、IGF、G MF、aFGF、bFGF、NT3、NT5、HARP/プレイオトロフィンな ど;アポリポタンパク質:ApoAI、ApoAIV、ApoEなど、ジストロ フィンもしくはミニジストロフィン、嚢胞性繊維症に伴うタンパク質CFTR、 腫瘍サプレッサー:P53、Rb、RaplA、DCC、k−rev、凝固に含 まれる因子:因子VII、VIII、IX、DNA修復に含まれる遺伝子、自殺 遺伝子(チミジンキナーゼ、シトシンデアミナーゼ)から選ばれるタンパク質産 物をコードすることを特徴とする請求の範囲第10項に記載のアデノウィルス。 12.異種DNA配列がプロモーターの調節下における治療的遺伝子を含むこ とを特徴とする請求の範囲第9〜11項に記載のアデノウィルス。 13.プロモーターが構成的、調節的及び/又は組織−特異的プロモーターで あることを特徴とする請求の範囲第12項に記載のアデノウィルス。 14.プロモーターがウィルスのプロモーターであることを特徴とする請求の 範囲第13項に記載のアデノウィルス。 15.プロモーターがElA、MLP、CMV及びLTR−RSVプロモータ ーから選ばれることを特徴とする請求の範囲第14項に記載のアデノウィルス。 16.異種DNA配列が治療的遺伝子及びプロモーターの間に分泌配列も含む ことを特徴とする請求の範囲第12項に記載のアデノウィルス。 17.異種DNA配列が治療的遺伝子及びマーカー遺伝子、好ましくはβ−ガ ラクトシダーゼ遺伝子を含むことを特徴とする請求の範囲第1〜16項の1つに 記載のアデノウィルス。 18.そのゲノムの、少なくとも標的細胞におけるその複製に必要な領域を含 まないことを特徴とする請求の範囲第1〜17項の1つに記載のアデノウィルス 。 19.Ad5又はAd2型ヒトアデノウィルス、あるいはCAV−2型イヌア デノウィルスであることを特徴とする請求の範囲第18項に記載のアデノウィル ス。 20.1種又はそれ以上の請求の範囲第1〜19項の1つに記載の欠失組み換 えアデノウィルスを含む製薬学的組成物。 21.注射可能な形態であることを特徴とする請求の範囲第20項に記載の製 薬学的組成物。 22.104〜1014pfu/ml、好ましくは106〜1010pfu/mlの 欠失組み換えアデノウィルスを含むことを特徴とする請求の範囲第20又は21 項に記載の製薬学的組成物。 23.請求の範囲第1〜19項の1つに記載のアデノウィルスにより改変され ていることを特徴とする哺乳類細胞。 24.ヒト細胞であることを特徴とする請求の範囲第23項に記載の 細胞。 25.造血細胞、特にCD34又は腫瘍細胞であることを特徴とする請求の範 囲第24項に記載の細胞。 26.組み換えAAVの製造のための請求の範囲第6項に記載のアデノウィル スの利用。 27.生産的細胞を請求の範囲第6項に記載のアデノウィルスに感染させ、r ep及びcap遺伝子を有するプラスミドを用いてトランスフェクションするこ とを特徴とする請求の範囲第26項に記載の利用。 28.生産的細胞を請求の範囲第6項に記載のアデノウィルス、ならびにre p及びcap遺伝子を有するアデノウィルスに共感染させることを特徴とする請 求の範囲第26項に記載の利用。 29.生産的細胞がこれらのゲノム中に組み込まれたrep及びcap遺伝子 を含み、請求の範囲第6項に記載のアデノウィルスに感染させられることを特徴 とする請求の範囲第26項に記載の利用。 30.生産的細胞が細胞293であることを特徴とする請求の範囲第26〜2 9項に記載の利用。 31.さらにrep及びcap遺伝子のための発現カセットを含むことを特徴 とする請求の範囲第6項に記載のアデノウィルス。 32.E4領域以外のウィルス遺伝子全体が欠けていることを特徴とする請求 の範囲第31項に記載のアデノウィルス。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9402445A FR2716893B1 (fr) | 1994-03-03 | 1994-03-03 | Virus recombinants, leur préparation et leur utilisation thérapeutique. |
FR94/02445 | 1994-03-03 | ||
PCT/FR1995/000233 WO1995023867A1 (fr) | 1994-03-03 | 1995-02-28 | Adenovirus recombinants integratifs, leur preparation et leur utilisation therapeutique |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09509578A true JPH09509578A (ja) | 1997-09-30 |
JP3755827B2 JP3755827B2 (ja) | 2006-03-15 |
Family
ID=9460633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52273095A Expired - Fee Related JP3755827B2 (ja) | 1994-03-03 | 1995-02-28 | 組み込み可能な組み換えアデノウィルス、それらの製造及びそれらの治療的利用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US6033885A (ja) |
EP (1) | EP0748385A1 (ja) |
JP (1) | JP3755827B2 (ja) |
AU (1) | AU1852695A (ja) |
CA (1) | CA2184113A1 (ja) |
FR (1) | FR2716893B1 (ja) |
IL (1) | IL112860A (ja) |
WO (1) | WO1995023867A1 (ja) |
ZA (1) | ZA951803B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007161704A (ja) * | 2005-12-09 | 2007-06-28 | Koshi Tei | 神経損傷を処置するためのまたは神経細胞を再生するための組成物 |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0575518A1 (en) | 1991-03-06 | 1993-12-29 | Board Of Regents, The University Of Texas System | Methods and compositions for the selective inhibition of gene expression |
US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
US5856152A (en) * | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
IL116816A (en) * | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
US6752987B1 (en) | 1995-02-28 | 2004-06-22 | The Regents Of The University Of California | Adenovirus encoding human adenylylcyclase (AC) VI |
JP3961019B2 (ja) | 1995-02-28 | 2007-08-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 遺伝子転移媒介の血管形成療法 |
FR2735789B1 (fr) * | 1995-06-23 | 1997-07-25 | Centre Nat Rech Scient | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant |
US5801030A (en) * | 1995-09-01 | 1998-09-01 | Genvec, Inc. | Methods and vectors for site-specific recombination |
US6207457B1 (en) * | 1995-09-08 | 2001-03-27 | Avigen, Inc. | Targeted nucleotide sequence delivery and integration system |
WO1997015679A1 (en) * | 1995-10-27 | 1997-05-01 | The Trustees Of The University Of Pennsylvania | Recombinant viruses containing mobile genetic elements and methods of use in gene therapy |
AU1867297A (en) * | 1995-11-17 | 1997-06-05 | Wolfgang M. Franz | Gene-therapeutic nucleic acid construct, production of same and use of same in the treatment of heart disorders |
FR2741358B1 (fr) * | 1995-11-17 | 1998-01-02 | Centre Nat Rech Scient | Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn |
DE19608753C1 (de) * | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
DE19608751B4 (de) * | 1996-03-06 | 2006-05-18 | Medigene Ag | Verwendung eines Adeno-assoziierten Virus-Vektors zur Steigerung der Immunogenität von Zellen |
WO1997045550A2 (en) * | 1996-05-31 | 1997-12-04 | Baxter International Inc. | Mini-adenoviral vector |
US6132989A (en) * | 1996-06-03 | 2000-10-17 | University Of Washington | Methods and compositions for enhanced stability of non-adenoviral DNA |
IL127692A0 (en) * | 1996-07-01 | 1999-10-28 | Rhone Poulenc Rorer Sa | Method for producing recombinant adenovirus |
AU2004201075B2 (en) * | 1996-07-01 | 2005-05-26 | Centelion S.A.S. | Method for producing recombinant adenovirus |
FR2750433B1 (fr) * | 1996-07-01 | 1998-08-14 | Rhone Poulenc Rorer Sa | Procede de production d'adenovirus recombinants |
US6054467A (en) * | 1996-07-05 | 2000-04-25 | Sidney Kimmel Cancer Center | Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis |
US5958892A (en) | 1996-07-30 | 1999-09-28 | Board Of Regents, The University Of Texas System | 2-methoxyestradiol-induced apoptosis in cancer cells |
WO1998010087A1 (en) * | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
US5866552A (en) * | 1996-09-06 | 1999-02-02 | The Trustees Of The University Of Pennsylvania | Method for expressing a gene in the absence of an immune response |
US6489167B1 (en) * | 1996-09-25 | 2002-12-03 | The Government Of The United States As Represented By The Secretary Of The Department Of Human Services | Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic Togavirus vectors |
US6403370B1 (en) | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
IT1291135B1 (it) * | 1997-04-08 | 1998-12-29 | Angeletti P Ist Richerche Bio | Vettori ricombinanti utilizzabili in terapia genica |
WO1998046778A1 (en) * | 1997-04-11 | 1998-10-22 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Transgenomic viruses and the use thereof |
WO1998054345A1 (en) * | 1997-05-30 | 1998-12-03 | Baxter International Inc. | Mini-adenoviral vector |
US6251677B1 (en) | 1997-08-25 | 2001-06-26 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV virus and methods of use thereof |
US6696423B1 (en) | 1997-08-29 | 2004-02-24 | Biogen, Inc. | Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
WO1999018227A1 (en) * | 1997-10-08 | 1999-04-15 | Advanced Research And Technology Institute | Chimeric parvovirus-based recombinant vector system that specifically targets the erythroid lineage |
AU759573B2 (en) | 1997-12-23 | 2003-04-17 | Crucell Holland B.V. | Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal DNA of target cells |
DE19827457C1 (de) | 1998-06-19 | 2000-03-02 | Medigene Ag | Strukturprotein von AAV, seine Herstellung und Verwendung |
US6759237B1 (en) * | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
US6491907B1 (en) * | 1998-11-10 | 2002-12-10 | The University Of North Carolina At Chapel Hill | Recombinant parvovirus vectors and method of making |
US6387368B1 (en) | 1999-02-08 | 2002-05-14 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV virus and methods of use thereof |
US7314912B1 (en) | 1999-06-21 | 2008-01-01 | Medigene Aktiengesellschaft | AAv scleroprotein, production and use thereof |
DE19933288A1 (de) | 1999-07-15 | 2001-01-18 | Medigene Ag | Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung |
DE19933719A1 (de) | 1999-07-19 | 2001-01-25 | Medigene Ag | Strukturprotein in Adeno-assoziiertem Virus mit veränderten chromatographischen Eigenschaften, seine Herstellung und Verwendung |
WO2001048164A2 (en) | 1999-12-27 | 2001-07-05 | The Regents Of The University Of California | Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure |
US6916635B2 (en) * | 2000-10-02 | 2005-07-12 | The Research Foundation Of State University Of New York | Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof |
WO2002092786A2 (en) * | 2001-03-26 | 2002-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | A helper dependent adenoviral vector system and methods for using the same |
US20030229062A1 (en) * | 2001-12-07 | 2003-12-11 | The Regents Of The University Of California | Treatments for age-related macular degeneration (AMD) |
JP2005511713A (ja) * | 2001-12-07 | 2005-04-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア | 加齢性黄斑変性についての処置 |
US7470659B2 (en) | 2001-12-07 | 2008-12-30 | The Regents Of The University Of California | Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM) |
EP1453536A4 (en) * | 2001-12-12 | 2009-08-26 | Mayne Pharma Int Pty Ltd | COMPOSITION FOR PRESERVING VIRUSES |
AU2003300076C1 (en) | 2002-12-30 | 2010-03-04 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
EP2373338B1 (en) | 2008-12-03 | 2017-02-15 | The Johns Hopkins University | Annexina2 as immunological target |
JP2018506530A (ja) | 2015-01-30 | 2018-03-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 脊柱軟膜下遺伝子送達システム |
AU2016259976B2 (en) * | 2015-05-08 | 2021-10-14 | Children's Medical Research Institute | Promoters for expression of heterologous genes |
US20180305666A1 (en) | 2015-10-19 | 2018-10-25 | University Of Maryland, Baltimore | Methods for generating engineered human primary blood dendritic cell lines |
WO2017172606A1 (en) | 2016-03-28 | 2017-10-05 | The Regents Of The University Of California | Method and composition for treating neuronal hyper-excitability |
US11560412B2 (en) | 2016-04-01 | 2023-01-24 | University Of Maryland, Baltimore | Compositions comprising GRIM-19 therapeutics and methods of use |
KR20230125339A (ko) * | 2016-04-15 | 2023-08-29 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Ii형 점액다당류증의 치료를 위한 유전자 요법 |
WO2018150271A1 (en) | 2017-02-17 | 2018-08-23 | Lonza Ltd. | Mammalian cells for producing adeno-associated viruses |
BR112020005249A2 (pt) | 2017-09-22 | 2020-09-24 | The Trustees Of The University Of Pennsylvania | terapia de gene para tratar mucopolissacaridose tipo ii |
US20210261982A1 (en) * | 2018-04-29 | 2021-08-26 | University Of Massachusetts | Raav-mediated nuclease-associated vector integration (raav-navi) |
WO2023083750A1 (en) | 2021-11-09 | 2023-05-19 | The Francis Crick Institute Limited | Viral adaptors and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173414A (en) * | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5252479A (en) * | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
US5587308A (en) * | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
CA2106260A1 (en) * | 1992-09-17 | 1994-03-18 | Robert M. Kotin | Human adeno-associated virus integration site dna and uses thereof |
-
1994
- 1994-03-03 FR FR9402445A patent/FR2716893B1/fr not_active Expired - Fee Related
-
1995
- 1995-02-28 EP EP95910605A patent/EP0748385A1/fr not_active Withdrawn
- 1995-02-28 WO PCT/FR1995/000233 patent/WO1995023867A1/fr not_active Application Discontinuation
- 1995-02-28 AU AU18526/95A patent/AU1852695A/en not_active Abandoned
- 1995-02-28 US US08/702,573 patent/US6033885A/en not_active Expired - Fee Related
- 1995-02-28 CA CA002184113A patent/CA2184113A1/fr not_active Abandoned
- 1995-02-28 JP JP52273095A patent/JP3755827B2/ja not_active Expired - Fee Related
- 1995-03-02 IL IL112860A patent/IL112860A/en not_active IP Right Cessation
- 1995-03-03 ZA ZA951803A patent/ZA951803B/xx unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007161704A (ja) * | 2005-12-09 | 2007-06-28 | Koshi Tei | 神経損傷を処置するためのまたは神経細胞を再生するための組成物 |
Also Published As
Publication number | Publication date |
---|---|
US6033885A (en) | 2000-03-07 |
EP0748385A1 (fr) | 1996-12-18 |
IL112860A (en) | 2006-10-05 |
WO1995023867A1 (fr) | 1995-09-08 |
IL112860A0 (en) | 1995-06-29 |
AU1852695A (en) | 1995-09-18 |
ZA951803B (en) | 1996-01-09 |
JP3755827B2 (ja) | 2006-03-15 |
CA2184113A1 (fr) | 1995-09-08 |
FR2716893B1 (fr) | 1996-04-12 |
FR2716893A1 (fr) | 1995-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3755827B2 (ja) | 組み込み可能な組み換えアデノウィルス、それらの製造及びそれらの治療的利用 | |
AU2022200502B2 (en) | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof | |
KR100403708B1 (ko) | 재조합아데노-수반바이러스(aav)제조방법및이의용도 | |
JP3995259B2 (ja) | 動物起源のアデノウイルスベクターおよび遺伝子治療におけるそれらの使用 | |
JP3565859B2 (ja) | 改良されたアデノウイルスおよびその使用法 | |
CN113302201A (zh) | 重组病毒载体和用于产生所述重组病毒载体的核酸 | |
JPH10507061A (ja) | アデノウイルス中にパッケージされたプラスミドdnaを用いる遺伝子送達ベクターおよびパッケージング細胞株 | |
JPH10507928A (ja) | ハイブリッドアデノウイルス−aavウイルスおよびその使用方法 | |
JPH11507835A (ja) | 組換えアデノウイルス、aavを作製するためのその使用、相補的細胞系、及び、該アデノウイルスを含む医薬組成物 | |
JP2001500497A (ja) | 組換えアデノ随伴ウイルスに指図される遺伝子治療の方法 | |
JP2001526900A (ja) | 標的細胞の染色体dnaへの外来遺伝子情報の組み込みに有用な、アデノ随伴ウイルスおよびアデノウイルスのキメラ組換えウイルス | |
EP0964922A1 (en) | Methods for optimization of gene therapy by recursive sequence shuffling and selection | |
JP4376454B2 (ja) | アデノウイルスベクター及び相同組換えイベントの低減方法 | |
JP4386971B2 (ja) | スプライシング配列を含んでなる組換えアデノウイルスベクター | |
US6806080B2 (en) | Hybrid vectors for gene therapy | |
US7060497B2 (en) | Adeno-associated viral vector-based methods and compositions for introducing an expression cassette into a cell | |
JP2002543792A (ja) | ベクターによるトランスポゾン配列の供給及び組込み | |
JPH10506018A (ja) | 不活化IVa2遺伝子を有する欠陥組換えアデノウィルス | |
CZ296600B6 (cs) | Virový vektor obsahující replikující se DNA, zpusob prípravy této DNA a farmaceutická kompozice obsahující virový vektor | |
Zhang et al. | Random integration analysis of recombinant adeno-associated virus 6 packaged in Sf9 insect cells | |
US20020001579A1 (en) | Nonhuman helper-dependent virus vector | |
CN115244181A (zh) | 阿司匹林化合物在增加核酸表达中的新型用途 | |
Imai | Gene therapy for the treatment of renal disease: prospects for the future | |
Zhang | Adenovirus-based gene therapy approaches for hemophilia B | |
Li et al. | 110. Mechanistic Study of Recombinant Adeno-Associated Virus (AAV) DNA End-Joining |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050111 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050308 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050418 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050711 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20051213 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20051219 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |